Scinai Immunotherapeutics Files 2024 Annual Report

TL;DR

Scinai Immunotherapeutics filed its 2024 20-F, check financials.

AI Summary

Scinai Immunotherapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as BiondVax Pharmaceuticals Ltd. until June 24, 2014, is based in Jerusalem, Israel, and operates in the biological products sector. The filing was made on May 7, 2025.

Why It Matters

This filing provides investors with a comprehensive overview of Scinai Immunotherapeutics' financial performance and business operations for the fiscal year 2024, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a biotechnology company, Scinai Immunotherapeutics is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.

Key Numbers

• 2024 — Fiscal Year End (The period covered by the annual report.)
• 20250507 — Filing Date (The date the 20-F was submitted to the SEC.)

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Filer of the 20-F
• BiondVax Pharmaceuticals Ltd. (company) — Former name of Scinai Immunotherapeutics Ltd.
• 20250507 (date) — Filing date of the 20-F
• 20241231 (date) — Fiscal year end date
• 001-37353 (dollar_amount) — SEC file number

FAQ

From the Filing

0001213900-25-040402.txt : 20250507 0001213900-25-040402.hdr.sgml : 20250507 20250507074220 ACCESSION NUMBER: 0001213900-25-040402 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 107 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 25919331 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 20-F 1 ea0239669-20f_scinai.htm ANNUAL REPORT      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 20-F   (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934   OR   ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the fiscal year ended December 31 , 2024   OR   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from              to                 OR   ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of event requiring this shell company report:   For the transition period from ____________ to ____________   Commission file No. 001-37353   Scinai Immunotherapeutics Ltd. (Exact name of Registrant as specified in its charter)   N/A (Translation of Registrant’s name into English)   ISRAEL (Jurisdiction of incorporation or organization)   Jerusalem BioPark , 2nd floor Hadassah Ein Kerem Campus Jerusalem , Israel (+972) 8-930-2529 (+972) 8-930-2531 (facsimile) (Address of principal executive offices)   Amir Reichman , Chief Executive Officer (+972) 8-930-2529 (+972) 8-930-2531 (facsimile) (Name, telephone, e-mail and/or facsimile number and address of company contact person)   Securities registered or to be registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered American Depositary Shares, each representing 4,000 ordinary share, no par value   SCNI   Nasdaq Capital Market Ordinary Shares, no par value*           * Not for trading on The Nasdaq Capital Market, but listed above only in connection with the registration of American Depositary Shares.   Securities registered or to be registered pursuant to Section 12(g) of the Act.   None (Title of Class)   Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.   None (Title of Class)       Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 3,411,983,584 ordinary shares, no par value   Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes ☐ No ☒   If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchan